EUVIMEDEUVIMED entdecken
Crossref

Comment on Young et al. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study

Yongxin Zhang, Jianwei Liu, Yuhuai Wu

Diabetes Care · 01.12.2026 · 49 (12) · e220-e221

DOI: 10.2337/dc26-1794 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 20.11.2026. Verfasst von Yongxin Zhang und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Zhang, Y., Liu, J., & Wu, Y. (2026). Comment on Young et al. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study. Diabetes Care, 49(12), e220-e221. https://doi.org/10.2337/dc26-1794

Vancouver

Zhang Y, Liu J, Wu Y. Comment on Young et al. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study. Diabetes Care. 2026;49(12):e220-e221. doi:10.2337/dc26-1794

BibTeX
@article{Zhang2026,
  author = {Zhang, Yongxin and Liu, Jianwei and Wu, Yuhuai},
  title = {Comment on Young et al. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study},
  journal = {Diabetes Care},
  year = {2026},
  volume = {49},
  number = {12},
  pages = {e220--e221},
  doi = {10.2337/dc26-1794}
}
Kostenlos starten →